Validation of AML-Score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia

: The AML-Score is a web-based tool that was designed to predict the risk of complete remission and early mortality in older patients with acute myeloid leukemia being treated with traditional induction chemotherapy. This retrospective study of 40 patients assesses the validity of the AML-Score in a cohort of older patients with secondary AML who received induction chemotherapy with the newer agent, CPX-351. Results of the study show that the AML-Score trends in the correct direction for predicting CR and EM in this patient population and may facilitate oncologist decision making when considering treatment with CPX-351.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research